Kiyuk Chang
Overview
Explore the profile of Kiyuk Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
237
Citations
1768
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bu S, Kim C, Lim S, Jang J, Park M, Choi I, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461916.
PMID: 40014346
Importance: The potential benefits of P2Y12 inhibitor deescalation for acute myocardial infarction after percutaneous coronary intervention may be influenced by body mass index (BMI). Objectives: To investigate the association of...
2.
Kang S, Moon J, Lee S, Kim S, Kang J, Kim H, et al.
Circ Genom Precis Med
. 2025 Feb;
:e004998.
PMID: 39945096
No abstract available.
3.
Jo J, Lee S, Joh H, Kim H, Kim J, Hong Y, et al.
Crit Care
. 2025 Feb;
29(1):65.
PMID: 39915828
Background: Although potent P2Y inhibitors, such as ticagrelor and prasugrel, are standard treatment in patients with acute myocardial infarction (AMI), evidence for their efficacy and safety compared with clopidogrel is...
4.
Jang J, Ga-In Y, Jongwha A, Bae J, Yun-Ho C, Kang M, et al.
Thromb Haemost
. 2024 Dec;
PMID: 39657950
Aim To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI). Methods and results Patients both at high ischaemic...
5.
Ahn H, Chu H, Her A, Jeong Y, Kim B, Joo H, et al.
J Cardiovasc Pharmacol Ther
. 2024 Nov;
29:10742484241298150.
PMID: 39552592
Calcium channel blockers (CCBs) are frequently co-administered with clopidogrel in cardiovascular disease. Although an inhibitory drug interaction exists between them, comprehensive large-scale studies for its validation are lacking. We investigated...
6.
Vu M, Shiwakoti S, Ko J, Bang G, Lee E, Kim E, et al.
Biochem Pharmacol
. 2024 Nov;
230(Pt 3):116614.
PMID: 39515588
Calcific aortic valve disease (CAVD) is a considerable health burden with a lack of effective therapeutic options. There is an urgent need to develop interventions that inhibit the osteogenic transformation...
7.
Choo E, Moon D, Choi I, Lim S, Lee J, Kang D, et al.
Cardiovasc Diabetol
. 2024 Nov;
23(1):396.
PMID: 39501240
Backgrounds: High-intensity statin is recommended for patients undergoing percutaneous coronary intervention (PCI), and ezetimibe is recommended to be added in patients not achieving low-density lipoprotein cholesterol (LDL-C) targets. Moderate-intensity statin...
8.
Kim H, Lee K, Choo E, Hwang B, Kim J, Kim C, et al.
J Am Heart Assoc
. 2024 Sep;
13(18):e034870.
PMID: 39248255
Background: The prognostic implication of mildly reduced ejection fraction (mrEF) after acute myocardial infarction has not been clearly demonstrated. We investigated the long-term risk of cardiovascular death and its predictors...
9.
Kim K, Kim S, Lee K, Yoon A, Hwang B, Choo E, et al.
J Am Heart Assoc
. 2024 Aug;
13(16):e034920.
PMID: 39158557
Background: Little is known about the characteristics and long-term clinical outcomes of patients with heart failure with improved ejection fraction (HFimpEF) after acute myocardial infarction. Methods And Results: From a...
10.
Kim J, Hong S, Cha J, Lim S, Joo H, Park J, et al.
BMC Med
. 2024 Aug;
22(1):335.
PMID: 39148087
Background: Concomitant use of clopidogrel and proton pump inhibitor (PPI) is common, but PPI may reduce the antiplatelet effects of clopidogrel in patients undergoing percutaneous coronary intervention (PCI). We evaluated...